Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept conversion in maintenance kidney transplant recipients
NCT01820572Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2013
- Primary completion
- Oct 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of belatacept in kidney transplantation (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants Who Survive With a Functional Graft at 24 months. Started Mar 2013; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT01820572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01820572.